Wilfried Schroyens

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

Viggo Van Tendeloo, Ann Van de Velde, Ann Van Driessche et al. · Proceedings of the National Academy of Sciences · 2010 · 370 citations · Full text

Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma

Berthe M.P. Aleman, John Raemaekers, Umberto Tirelli et al. · New England Journal of Medicine · 2003 · 306 citations · Full text

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Sébastien Anguille, Ann L. Van de Velde, Evelien Smits et al. · Blood · 2017 · 228 citations · Full text

Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia

Jan Michiels, Zwi Berneman, Wilfried Schroyens et al. · Platelets · 2006 · 111 citations

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial

Natacha Heutte, Hans‐Henning Flechtner, Nicolas Mounier et al. · The Lancet Oncology · 2009 · 103 citations

Quality Of Life, Lymphoid Neoplasia, 10-Year Follow-up +6